August 11, 2025

Second Quarter 2025 Financial Results & Corporate Update

This presentation is for investor relations purposes only - Not for product promotional purposes

Agenda

1. Opening Remarks
2. Q2 2025 Highlights & Recent Accomplishments
3. Our Pipeline
4. Capitalizing on Market Leadership
5. CARVYKTI® Performance Overview
6. Financial Performance
7. Q&A

Ying Huang, PhD
Chief Executive Officer

Alan Bash
President of CARVYKTI®

Jessie Yeung
Interim Chief Financial Officer

Forward-looking Statements

This presentation has been prepared by Legend Biotech Corporation ("Legend Biotech" or the "Company") solely for information purpose and does not contain all relevant information relating to the Company.

The safety and efficacy of the agents and/or uses under investigation discussed in this presentation have not been established, except to the extent specifically provided by marketing authorizations previously received from relevant health authorities. Further, for investigational agents and/or uses, the Company cannot guarantee health authority approval or that such agents and/or uses will become commercially available in any country.

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Legend Biotech's own internal estimates and research. While Legend Biotech believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Legend Biotech believes its internal research is reliable, such research has not been verified by any independent source.

Statements in this presentation about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995.

These statements include, but are not limited to, statements relating to Legend Biotech's strategies and objectives; statements relating to CARVYKTI® (ciltacabtagene autoleucel; cilta-cel), including patient population of CARVYKTI®, Legend Biotech's expectations for CARVYKTI®, including manufacturing expectations for CARVYKTI®; and statements about regulatory submissions for CARVYKTI®, statements related to Legend Biotech's ability to achieve operating profit; statements related to Legend Biotech's ability to fund its operations into 2026 and Legend Biotech's anticipated profitability excluding unrealized foreign exchange losses in 2026; the progress of such submissions with the FDA, the EMA and other regulatory authorities; expected results and timing of clinical trials; Legend Biotech's expectations on advancing its pipeline and product portfolio, including TaVec; and the potential benefits of Legend Biotech's product candidates. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech's patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the "Risk Factors" section of Legend Biotech's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on March 11, 2025 and Legend Biotech's other filings with the SEC.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this presentation as anticipated, believed, estimated or expected. Any forward-looking statements contained in this presentation speak only as of the date of this presentation. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

LEGEND BIOTECH

Non-IFRS financial metrics

This presentation refers to certain non-IFRS financial metrics.

We use Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Share (which we sometimes refer to as “Adjusted EPS”, or “ANI per Share”, respectively) as performance metrics. Adjusted Net Income (Loss) and ANI per Share are not defined under IFRS, are not a measure of operating income, operating performance, or liquidity presented in accordance with IFRS, and are subject to important limitations. Our use of Adjusted Net Income (Loss) has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under IFRS. For example: (i) although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted Net Income (Loss) does not reflect cash capital expenditure requirements for such replacements or for new capital expenditure requirements; (ii) Adjusted Net Income (Loss) excludes unrealized foreign exchange gain (loss) which was primarily resulted from changes in the intercompany loan balances and cash balances as a result of exchange rate changes between USD and EURO; (iii) Adjusted Net Income (Loss) does not reflect changes in, or cash requirements for, our working capital needs; and (iv) Adjusted Net Income (Loss) excludes such as share based compensation expense, which has been, and will continue to be fore the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy. Also, our definition of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per share may not be the same as similarly titled measures used by other companies.

However, we believe that providing information concerning Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Share enhances an investor’s understanding of our financial performance. We use Adjusted Net Income (Loss) as a performance metric that guides management in its operations of planning for the future of the business. We believe that Adjusted Net Income (Loss) provides a useful measure of our operation performance from a period to period by excluding certain items that we believe are not representative of our core business. We define Adjusted Net Income (Loss) as net income (loss) adjusted for (1) non-cash items such as depreciation and amortization, share-based compensation, and impairment loss and (2) unrealized foreign exchange gain or loss mainly related to intercompany loan balances and cash deposit balances as a result of exchange rate changes between USD and EUR. Adjusted Net Income (Loss) per Share is computed by dividing Adjusted Net Income (Loss) by the weighted average shares outstanding.

Reconciliations of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Share to the most directly comparable IFRS measures are included at the end of this presentation.

Ying Huang, PhD

Chief Executive Officer

Q2 2025 Highlights & Recent Accomplishments

Q2 2025 Highlights

- CARVYKTI® Net Trade Sales of **$439M**
  - **136%** YoY growth, driven by continued share gains and capacity expansion
- **>7,500** clinical and commercial patients treated to date
- FDA approved a supplemental BLA for CARVYKTI to **remove the risk evaluation and mitigation strategy (REMS)**
  - Product labeling was updated to align with REMS elimination, also reductions of certain patient monitoring requirements
- **Appointed Peter Salovey, Ph.D.** as Lead Independent Director

Select Presentations at ASCO[1]

- Presented **CARTITUDE-1** analysis demonstrating 1/3 of patients with relapsed and refractory MM[2] remained progression-free for ≥5 years with no maintenance therapy
- Based on Phase 3 **CARTITUDE-4** study subgroup analyses, CARVYKTI delivered positive clinical outcomes for patients with high-risk cytogenetics
- In a Phase 1 study, **LB1908** demonstrated encouraging antitumor activity with a manageable safety / tolerability profile
- In a Phase 1 dose-escalating study evaluating **LB2102**, no dose-limiting toxicities were reported, and a preliminary efficacy signal was observed up to four dose levels

1. 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
2. MM = Multiple Myeloma

CARVYKTI is the first MM CAR-T to show long-term survival

CARTITUDE-1: ≥5-year remission and survival after treatment with CARVYKTI

Among these 32 patients:	
Median age	60 years
# of prior lines of therapy (LOT)	6.5 (range, 3-14)
HR cytogenetics	23.3%
Extramedullary disease	12.5%
Triple class refractory	90.6%
Penta drug refractory	46.9%

- For these 32 patients, prior to enrollment in CARTITUDE-1, median time from start of last LOT to progression was 4 months (range, 0.7–48.6).
- Overall, at 61.3 month median follow-up in CARTITUDE-1 (N=97), median OS was 60.7 months (95% CI, 41.9–NE).

Of 97 patients treated, **32 (33%) remained alive and progression free for ≥5 years after CARVYKTI, without further multiple myeloma treatment**

"These results...are remarkable, given the historically dismal prognosis for this population." – Dr. Sundar Jagannath[1]

1. Jagannath, Sundar, et al. "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma." Journal of Clinical Oncology; https://doi.org/10.1200/JCO-25-00760

CARVYKTI improved PFS and OS across CARTITUDE-4 subgroups

CARVYKTI consistently improved progression free survival (PFS) and overall survival (OS) compared with standard of care (SOC) in patients with standard risk and high risk[1]

Kaplan-Meier analysis of patients with standard-risk and high-risk cytogenetics



Patients at risk																
High risk, SOC	132	111	79	65	52	42	37	31	28	23	20	7	3	0	0	0
High risk, cilta-cel	123	106	102	96	92	87	84	76	73	70	55	31	14	7	2	0
Standard risk, SOC	70	58	50	47	41	36	35	32	32	29	27	18	9	1	1	0
Standard risk, cilta-cel	69	59	58	57	53	51	49	49	49	49	46	27	9	2	1	0



Patients at risk																
High risk, SOC	132	130	126	116	110	103	96	91	84	81	75	38	14	6	0	0
High risk, cilta-cel	123	121	115	111	105	103	102	98	95	93	83	50	23	14	5	0
Standard risk, SOC	70	69	62	61	57	55	54	52	49	48	48	29	18	5	3	0
Standard risk, cilta-cel	69	65	61	59	57	57	56	56	56	55	52	35	13	5	2	0

1. Sidana, Surbhi, et al. "Ciltacabtagene Autoleucel (Cilta-cel) vs Standard of Care (SOC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM): CARTITUDE-4 Survival Subgroup Analyses." American Society of Clinical Oncology (ASCO) Annual Meeting; May 30–June 3, 2025.

Leveraging Learnings to Further Improve CARVYKTI's Profile



1. Neurologic events include Movement and Neurocognitive treatment-emergent adverse events and Cranial Nerve Palsy.

Our Pipeline

CARVYKTI® (ciltacabtagene autoleucel) Suspension for IV Infusion

Ciltacabtagene Autoleucel Clinical Studies

BCMA-directed Autologous Therapy

PHASE 1	PHASE 2			PHASE 3		
LEGEND-2† RRMM NCT03090659	**CARTIFAN-1*** RRMM NCT03758417	**CARTITUDE-1*** RRMM NCT03548207	**CARTITUDE-2*** MM NCT04133636	**CARTITUDE-4*** RRMM 1-3 Prior Lines NCT04181827	**CARTITUDE-5*** NDMM Transplant Not Intended NCT04923893	**CARTITUDE-6*** NDMM Transplant Eligible NCT05257083

Johnson&Johnson

Additional Pipeline Assets

	PHASE 1				
Autologous Therapies	**AUTOIMMUNE†** (CD19 X CD20 X CD22)	**MM†** (CD19 X GPRC5D), (GPRC5D)	**COLORECTAL†** (GCC)	**SCLC & LCNEC‡#** (DLL3) NOVARTIS	**GASTRIC & PANCREATIC‡** (CLAUDIN 18.2)
Allogeneic Therapies	**AUTOIMMUNE** (CD19 X BCMA) (CD19 X CD70)	**NHL†** (CD20) CAR-αβ T	**NHL†** (CD19 X CD20) CAR-γδ T	**MM†** (BCMA) CAR-NK	
In Vivo Therapies	**NHL†** (CD19 X CD20)				

*In collaboration with Janssen, Pharmaceutical Companies of Johnson & Johnson. †Phase 1 investigator-initiated trial. ‡IND applications have been cleared by the U.S. FDA. #Subject to an exclusive license agreement with Novartis Pharma AG.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no assurance that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. Additionally, as some programs are still confidential, certain candidates may not be included in this list.
INDICATIONS: ALL: acute lymphoblastic leukemia; LCNEC: large cell neuroendocrine carcinoma; MM: multiple myeloma; NDMM: newly diagnosed multiple myeloma; NHL: non-Hodgkin lymphoma; RRMM: relapsed or refractory multiple myeloma; SCLC: small cell lung cancer
TARGETS: BCMA: B-cell maturation antigen; DLL3: delta-like ligand 3; GCC: guanylyl cyclase C; GPRC5D: G-protein coupled receptor, family C, group 5, member D

LEGEND BIOTECH

Leveraging Stand-Alone Cell Therapy Leadership *In Vivo*

TaVec (T-Cell Activation Vector) design and mechanism of action

TARGET
- Oncology and autoimmune indications

Mechanism of Action/Scientific Rationale
- Cocal glycoprotein in TaVec platform
- Provide T cell specificity, activation and safety
- Mutations in glycoprotein to block transduction of non-T cells

Clinical Development Strategy
- First few patients dosed for IIT studies in 2025
- Multiple US-IND enabling studies planned for oncology indications



1. Low-Density Lipoprotein Receptor

Capitalizing on Cell Therapy Leadership for Long-Term Growth

MARKET LEADING CAR-T IN MM

CARVYKTI™ (ciltacabtagene autoleucel) Suspension for IV Infusion

Now the **highest selling CAR-T in a single quarter**

First and only CAR-T therapy for MM with meaningful **progression free outcomes of ≥5 years**

Ongoing global launch with expansion into new markets

ROBUST PIPELINE

10 Pipeline Programs

- Hematologic Malignancies
- Solid Tumors
- Autoimmune Diseases

State-of-the-art R&D facility opening soon in Philadelphia

Partnership with Novartis for CAR-T therapies selectively targeting DLL3

STRONG FINANCIAL POSITION

$439 million

Net Trade Sales for 2Q 2025

Cash position of **~$1 billion** as of 6/30/2025

- Strong balance sheet
- Improving gross margins
- Expected profitability in 2026

1. Net Trade Sales Compound Annual Growth Rate from CARVYKTI launch through Q2 2025

LEGEND BIOTECH

Alan Bash

President of CARVYKTI®

A New Standard for CAR-T Launches

CARVYKTI® - NOW THE HIGHEST SELLING CAR-T THERAPY IN A SINGLE QUARTER WITH NTS CAGR of 80%[1]

ACHIEVED RECORD-BREAKING QUARTERLY SALES IN 12 QUARTERS



Data Source: Companies' public filings.

1. Net Trade Sales Compound Annual Growth Rate from CARVYKTI launch through Q2 2025

CARVYKTI® Uptake Continues

Continued market penetration, population in earlier lines of treatment represents significant opportunity for continued growth



	YoY Growth[1]	QoQ Growth[2]
U.S.	114%	13%
OUS	305%	59%
Global	136%	19%

- U.S. QoQ growth of 13% primarily driven by:
  - Continued strong demand with nearly 60% utilization in earlier line settings
- OUS QoQ growth of 59% primarily driven by:
  - Launch uptake in 11 markets

1. Q2 2025 vs Q2 2024; 2. Q2 2025 vs Q1 2025

Strong Momentum Across Supply and Demand Accelerates CARVYKTI's CAR-T Leadership in MM

Best-in-Class Manufacturing

- On track for **10,000 Annualized Doses by YE**
  - US – Approval of new Raritan facility section in 2H 2025
  - OUS – Initiation of commercial production at Tech Lane in 2H 2025
- Manufacturing **Efficiency Enhancements**
  - 97% Manufacturing Success Rate
  - Improved OOS[1] Rates
  - TAT[2] reduced to median 30 days, in line with bridging protocols

Demand Acceleration

- **Unprecedented progression-free outcomes for ≥5 years** for relapsed and refractory MM patients[1]
- Demonstrated **overall survival benefit**
- **REMS modifications** that improve quality of life for CARVYKTI patients
- **123 US Treatment Sites** Activated
- Recent **OUS launches**

1. Voorhees, et al. ASCO; May 30 – June 3; Chicago, IL, USA, & Virtual. Abstract 7607
2. Out of Spec
3. Turn Around Time from apheresis to release

LEGEND BIOTECH

Significant Opportunity to Reach More 2L+ MM Patients

Total Addressable MM Market Opportunity for CAR-T



Increasing Awareness of CARVYKTI®

Teams at ATCs[1]

- Raise CART-4 data awareness
- Outpatient opportunity education

Community Hematologists/Oncologists

- Support referrals and transition of care
- Expand access in community

Patients

- Educate patients and caregivers through multi-channel campaign

1. ATCs= Authorized Treatment Centers

Source: Company internal estimates.

LEGEND BIOTECH

Bringing CARVYKTI® Closer to US Multiple Myeloma Patients

Initial Site Type CAR-T Adoption	Early Community Channel CAR-T Adoption	Evolving Community Channel CAR-T Adoption
2022: 44 sites	**2025 YTD:** 123 Sites	**2026+:** Expanded reach to community
1	2	3
Academic Centers	Academic Centers & Affiliates Community/Regional Hospitals	Academic Centers & Affiliates Community/Regional Hospitals Community Practices & Networks

Rapidly Expanding Access for Patients Outside the US

2024 New Markets Launched


Germany


Switzerland


Austria


Brazil

YTD 2025 New Markets Launched


Denmark


Sweden


Belgium


Spain


Israel


UK


Portugal*


Australia*

- CARTITUDE-4 Overall Survival added to EU Label
- 213 Global Activated Treatment Sites

* Regulatory approval. Reimbursement and launch in planning phase.

Jessie Yeung

Interim Chief Financial Officer

Q2 2025 Financial Highlights











1. Adjusted Net Loss and Adjusted Net Loss per Share (on basic shares basis) are non-IFRS measures. Reconciliations of Adjusted Net Loss and Adjusted Net Loss Per Share to the most directly comparable IFRS measures are included at the end of this presentation. The definitions of these non-GAAP measures are at the beginning of this presentation.

This presentation is for investor relations purposes only - Not for product promotional purposes

Focused Investments in Commercialization and Pipeline



Q2 2025 OpEx Remained Flat vs. Q2 2024

- **Research and development (R&D) spend** was *$98.3 million* due to continuous R&D activities with:
  - Two ongoing frontline studies for cilta-cel
  - Three US IND enabling programs
  - 13 ongoing IIT trials
- **Selling and distribution (S&D) spend** was *$48.1 million* due to support of commercial activities for CARVYKTI , including expansion of the sales force to meet demand.
- **Administrative expenses** was *$32.6 million* due to increased staffing related expenses offset by lower infrastructure expenses.

Cash and cash equivalents, and time deposits of **$1.0 billion**

Executing Toward Anticipated Company Wide Profitability in 2026

KEY DRIVERS

COMMERCIAL

Further expand market leadership in Multiple Myeloma CAR-T therapies

Add overall survival to label

MANUFACTURING

Increasing manufacturing efficiency

Expanding capacity for 10,000 annualized doses exiting 2025

FINANCIAL

Scaling business with ~$1B cash position

Continued margin expansion

LEGEND BIOTECH

Q&A

Ying Huang, Ph.D.
Chief Executive Officer

Jessie Yeung
Interim Chief Financial Officer

Alan Bash
President of CARVYKTI®

Guowei Fang, Ph.D.
President of Research
and Development

Mythili Koneru, M.D., Ph.D.
Chief Medical Officer

Thank you!

Reconciliation of IFRS to Non-IFRS Metrics

	Three months ended June 30,	
($ in thousands, except per share data)	**2025**	**2024**
Net loss	(125,380)	(18,196)
Depreciation and amortization	5,854	5,369
Share-based compensation	18,697	21,739
Impairment loss	—	—
Unrealized foreign exchange loss/(gain) (included in Other income/(expense), net)	110,920	(11,419)
Adjusted net income/(loss) (ANI)	10,091	(2,507)
ANI per share:		
ANI per share – basic	0.03	(0.01)
ANI per share - diluted	0.03	(0.01)
Financials under IFRS		
Earnings per share – basic	(0.34)	(0.05)
Earnings per share – diluted	(0.34)	(0.05)
Shares – basic	368,281,125	365,204,154
Shares - diluted	368,271,125	365,204,154